Wednesday, May 11, 2022

The 2nd Annual Gene Therapy Summit To Share Insights On Safer Gene Therapy Programs

 The 2nd Annual Gene Therapy Summit will take place June 7-9, 2022, in Boston, MA. With a focus on effectively engaging genetic therapy patients, this is a must attend summit for individuals and companies that are serious about building safer and more meaningful gene therapy programs. The summit will unite patient advocacy and engagement leaders from gene therapy and gene editing drug developers, patient groups and patients themselves to address the specific challenges of patient engagement in genetic therapy and will generate actionable insights through detailed case studies and open discussions. 

As gene therapies proliferate and sector investment continues to grow rapidly, engaging with patients effectively at each stage of the processes has become a priority and a necessity to enhance efficacy.

During the comprehensive 3-day agenda you will hear directly from experts in patient advocacy at genetics companies including Spark Therapeutics, Ultragenyx, BioMarin, Global Genes, and CRISPR Therapeutics. Other speakers include Pfizer’s Senior Director of Policy & Public Affairs and the Deputy Director, Officer of Rare Diseases Research at NIH. 

These speakers and others will address important topics that include managing expectations across gene therapy development, navigating patient input on one-time transformative treatments with novel clinical trial designs combined with extensive follow-ups, and developing educational materials on gene therapy to raise awareness in collaboration with patient advocacy organizations. 

This is a unique opportunity to leverage the collective knowledge and experience of industry experts to ensure effective creation and implementation of patient-centric gene therapy programs.

Past attendees of the Gene Therapy Event Series have praised the event saying:

“Exciting new way of participating in scientific conference and discussion.” uniQure

“I found the presenters and participant patient engagement knowledge superb, as was their willingness to share.” 4D Molecular Therapeutics

“Incredibly positive and eye-opening experience for a scientist new to the field.” Novartis Gene Therapies

“Lots of useful information and good variety of perspectives.” Ten Bridge

The summit is hosted by Hanson Wade, a world leading conferences and data products organization that creates exclusive business conferences by gathering together the world’s smartest thinkers and doers. 

Register here to attend https://genetherapy-patient-engagement.com/take-part/register/.

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a financial news and content distribution company, one of 50+ brands within the InvestorBrandNetwork (“IBN”), that provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork

No comments:

Post a Comment